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Allelic variants implicated in drug absorption, distribution,
metabolism, and excretion (ADME) affect drug pharmacoki-
netic variability and have been increasingly recognized as
important factors in medical therapy. Our recently published
study found an association of thrombotic microangiopathy
(TMA) with high sirolimus serum levels in a cohort of 177
patients who received sirolimus and tacrolimus as GVHD
prophylaxis following allogeneic transplantation. By multi-
variable analysis, increased risk of TMA was associated with
day 14 serum sirolimus levels, prior aGVHD, and myeloa-
blative conditioning. In the current study we explore the
possible inﬂuence of ADME variants on sirolimus levels and
development of TMA in the same patient cohort.
We obtained archived DNA samples from the patients on our
TMA study and analyzed them using the iPLEX ADME PGx
panel and the MassARRAY Compact Analyzer. This panel is
based on the PharmADME Working Group list and covers
>99% of the Pharma ADME Core list; it interrogates 188
mutations and 12 copy number variation assays (in 36
pharmacogenetically relevant genes). Sirolimus levels were
measured at least weekly until day 100 with dose adjust-
ments made for target levels and/or clinical toxicity. Possible
associations between early sirolimus serum levels (day +14)
and assays were evaluated by the Kruskal-Wallis (non-
parametric) test and the false discovery rate was used to
control for multiple comparisons.
Using this Panel, 179 samples were genotyped, of which 173
showed high quality data. The average call rate for these
samples was 98.85% over 200 assays, with a median call rate
of 100%. Of these assays, 66 variants were identiﬁed that may
be of relevance to sirolimus metabolism; other assays were
excluded due to homzygosity or >10 % missing data. Using
this panel, we found 3 assays showing an association with
sirolimus drug level, rs1057910 (CYP2C9*3) at P¼ .04,
rs1799931 (NAT2*7) at P¼ .03, and rs2032582 (ABCB1
2677G>A/T) at P¼ .007. In addition, the 0-copy haplotype of
UGT2B17 also showed higher levels of sirolimus (P¼ .02).
These assays were also tested for an association with TMA,
showing a trend for increased TMA in the rs1799931
(NAT2*7) (P ¼ .08). However, after adjustment for multiple
testing, only rs2032582 maintained statistical signiﬁcance
due to the small sample size.
In conclusion, this pilot study of the iPLEX ADME PGx panel
showed feasiblity and provided high quality data. Despite the
limitation of small sample size, several genetic variants were
implicated in sirolimus levels and may warrant further
investigation. Future analysis should focus on speciﬁc gene
clusters or pathways and will require a large cohort to power
validation and training sets.443
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Introduction: Acute graft versus host disease (aGVHD) is
mediatedbyallogeneicTcell responses.Wehypothesized that
peripheral blood expansion of activated effector memory T
cell populations (TEM) following allogeneic hematopoietic
cell transplantation (HCT)would serve as a useful predictor of
aGVHD.
Methods: T cells were characterized in peripheral blood
samples from 16 consecutive pediatric allogeneic hemato-
poietic cell transplant (HCT) recipients. Samples were
collected prior to transplant and weekly following HCT until
day +42. Samples were incubated with ﬂuorochrome-
conjugated monoclonal antibodies directed against CD3,
CD8, CD38, CD45RA and CCR7, followed by red cell lysis and
ﬁxation. Samples were analyzed by ﬂow cytometry on
a FACSCanto ll ﬂow cytometer (BD Biosciences). Data was
analyzed using FCS Express (De Novo Software). TEM were
deﬁned as CD3+ lymphocytes which lacked expression of
CD45RA and CCR7. CD38 was used as a marker of activation.
Results: Patients had less than 65% of CD8+ CD38 bright
TEMs prior to transplant except for 1 patient with HLH who
had 99.8%, and was excluded from analysis. Patients who
developed aGVHD (n¼5), engraftment syndrome (n¼2), or
neither (n¼8) were observed to develop median maximum
expansions of CD8+ CD38bright TEM prior to or on the day of
diagnosis of aGVHD, or before day +42, of 49 cells/mcl (range
21-87), 5 cells/mcL (range 0.3-34) and 98cells/mcL (range
0.04-197), respectively (P ¼ .02, GVHD versus neither GVHD
nor engraftment syndrome). We observed that an absolute
number of CD8+ CD38 bright TEM greater than 20cells/mcL
was predictive of aGVHD with sensitivity of 100%, speciﬁcity
of 80%, and a negative predictive value of 100%. The cumu-
lative incidence of aGVHD in patients with greater than 20
CD8+ CD38 bright TEMs/mcL was 71%, and in patients with
less than 20cells/mcL, 0% (P < .01).
Conclusion: Quantiﬁcation of peripheral blood CD8+ CD38
bright TEM is a novel predictor of aGVHD.444
Novel Strategy for Non-Invasive Sampling of Epidermal
Cytokines Using a Skin Sampling Disc in Acute Skin Graft
Versus Host Disease and Engraftment Syndrome
Pooja Khandelwal 1, Kristi Smiley 1, Marty O. Visscher 2,3,
Angela M. Fieno 4, Raymond A. Grant 4, Joyce Villanueva 1,
Stella Davies 1, Alexandra Filipovich 1. 1 Bone Marrow
Transplantation and Immune Deﬁciency, Cincinnati Children's
Hospital Medical Center, Cincinnati, OH; 2 Pediatric Plastic
Surgery, Cincinnati Childrens Hospital Medical Center,
Cincinnati, OH; 3 Skin Sciences Program, Cincinnati Children's
Hospital Medical Center, Cincinnati, OH; 4 Global
Biotechnology, The Procter & Gamble Co., Mason, OH
Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341 S331Novel Strategy for Non-invasive Sampling of Epidermal
Cytokines Using a Skin Sampling Disc in Acute Skin Graft
versus Host Disease and Engraftment syndrome.
Introduction: The local cytokine milieu of target organs is
poorly described in acute graft versus host disease (aGVHD)
or engraftment syndrome (ES). A novel and noninvasive
methodology using D-Squame (Cuderm Dallas, TX) skin
sampling discs was utilized to collect the superﬁcial layer of
the stratum corneum in patients with acute skin GVHD or ES
and cytokines were measured from the keratinocytes which
adhered to the disc.
Methods: D-squame skin sampling discs were placed on the
forearm/wrist of 13 pediatric patients (ages 0.25 years-14
years) for 2 minutes and removed. In patients with acute skin
GVHD or ES, samples were obtained from the involved area
of the forearm/wrist. This procedurewas noted to be painless
and safe even for young infants. Superﬁcial keratinocytes
were sampled by the fully cured medical grade polyacrylate
ester adhesive on the disc. Cytokines were extracted from the
sampling discs using a buffer made of phosphate buffered
saline and 0.25 molar saline and analyzed using a 38 plex
human cytokine Milliplex MAP magnetic bead panel (EMD
Millipore Corp, Billerica, MA). Patients were divided into 4
groups; acute skin GVHD (n¼5), isolated engraftment
syndrome (n¼2), no acute GVHD or ES (n¼2) and healthy
pediatric controls (n¼4).
Results: IL1a was elevated in patients with aGVHD as
compared to healthy controls and patients who did not
develop aGVHD or ES (P ¼ .02 and P ¼ .04) Similarly IL1a was
elevated in ES as compared to patients who did not develop
aGVHD/ESor tohealthypediatric controls (P¼ .05 andP¼ .01).
Conclusions: These preliminary results demonstrate a novel
methodology to measure inﬂammatory cytokines locally in
acute skin GVHD and ES. With further patients and analysis,
newapproaches tomanagementmaybeindicated inthe future.
Figure 1. Average values of IL1a measured from the epidermis in patients with
ES, aGVHD, no ES or aGVHD and healthy pediatric controls.Table I
Response to alemtuzumab
Patient Organ(s)
Involved
Grade at
Alemtuzumab
Administration
Grade
at Day
28
Stage at
Alemtuzuma
Administrati
1 Skin III 0 III
GI III
2 Skin III III I
GI IV
Liver II
3 Skin III III II
GI III
4 Skin IV IV II
Liver IV
5 GI III 0 IV445
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Introduction: No clear second line agent exists for the
treatment of steroid refractory acute graft versus host
disease (SR-aGVHD) in children. Alemtuzumab is associated
with partial or complete responses in 50-94% of adult
patients. Studies are lacking in pediatric patients. The
optimal dose for young patients is unknown. Here we
present the ﬁrst phase of a single center dose-escalation
study of alemtuzumab for treatment of acute SR-aGVHD in
pediatric patients.
Methods: Patients were prospectively enrolled at the time of
diagnosis of grades II-IV acute GVHD. Patients were initially
treated with 4mg/kg/day methylprednisolone. If patients
failed to improve within 5 days, or worsened within 48
hours, SR-aGVHD was diagnosed and alemtuzumab was
administered at 0.2 mg/kg/day for 5 consecutive days
(maximum cumulative dose of 31mg). Additional 0.2mg/kg
doses were given on days 15, 22 and 29 (maximum dose
10mg/dose). Patients were monitored weekly for response.
Partial response (PR) was deﬁned as improvement in stage of
GVHD before 28 days following ﬁrst alemtuzumab admin-
istration, and complete response (CR) was deﬁned as
achievement of grade zero GVHD by 28 days following the
ﬁrst alemtuzumab administration.
Results: Six patients have been enrolled and 5 patients with
grades III (n¼4) or IV (n¼1) GVHD were treated with alem-
tuzumab so far. Median age was 12 years (range 1.9-27
years). Organs involved included skin (n¼4), gastrointestinal
tract (n¼4) and liver (n¼2) (Table I). Forty percent of patients
(n¼2) had a CR. Sixty percent of patients (n¼3) had a PR.
Adverse effects included transient neutropenia or
thrombocytopenia (n¼3), fever (n¼2), or asymptomatic
EBV viremia (n¼2) and/or adenovirus viremia (n¼2).
Conclusion: Alemtuzumab is an active agent for the treat-
ment of SR-a GVHD in pediatric patients. Further dose
escalation may increase complete response rates and estab-
lish an optimal regimen for successful therapy.b
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Stage
at day
6
Stage
at day
10
Stage
at day
14
Stage
at day
21
Stage
at day
28
I 0 0 0 0
III 0 0 0 0
0 0 0 0 0
III III III I II
II II II II II
I 0 End of study therapy
III III
I 0 End of study therapy
IV IV
I I I 0 0
